Real-world observational study on the efficacy and safety of first-line osimertinib treatment and on post-progression patterns of care in patients with epidermal growth factor receptor activating mutation positive (EGFRm +) advanced non-small-cell lung cancer (NSCLC) -Reiwa
Not Applicable
Recruiting
- Conditions
- Epidermal growth factor receptor activating mutation positive (EGFRm +) advanced non-small-cell lung cancer (NSCLC)
- Registration Number
- JPRN-UMIN000038683
- Lead Sponsor
- Public Health Research Foundation, Comprehensive Support Project for Oncology Research (CSPOR)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 700
Inclusion Criteria
Not provided
Exclusion Criteria
(1)atients whose treatment date for EGFR TKIs was prior to September 1, 2018. Patients judged by the physician to be inappropriate for enrollment in the study. (2)Patients judged by the physician to be inappropriate for enrollment in the study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method